Cover Image
Market Research Report
Product code 
1043513

Viral Vectors Market for Cell Therapy Market: Analysis and Opportunities

Published: | Kalorama Information | 109 Pages | Delivery time: 1-2 business days

Price

Back to Top
Viral Vectors Market for Cell Therapy Market: Analysis and Opportunities
Published: January 7, 2022
Kalorama Information
Content info: 109 Pages
Delivery time: 1-2 business days
  • ALL
  • Description
  • Table of Contents
Description

Viral vectors are useful tools used by molecular biologists to delivery genetic material into cells. Kalorama Information's “Viral Vectors Market Analysis and Opportunities ” reveals that viral vectors comprise a rising market that is expected to continue to grow as usage increases and novel technologies enter the market.

Viral vectors are the most effective means of gene transfer to modify specific cells or alter the expression of therapeutic genes. The choice of viral vector depends on the efficiency of transgene expression, ease of production, safety, toxicity, and stability. Viral vector technology is used in gene therapy and vaccines. It is an exciting and interesting time to be involved in the viral vector industry. The science is moving ahead and now the industry needs to industrialize and standardize the manufacturing and commercialization of products. The industry is moving in the direction of a standardized set-up and a closed automated system. This is especially true in gene therapy. Consequently, gene therapy products are transforming the treatment of cancers and genetic diseases. Viral vectors do not cause disease since they have been modified by removing the genes involved in replication and are replaced with therapeutic genes. Viral vectors are genetically stable, non-toxic for host cells and safe to handle.

Viruses attack the host and introduce genetic material as part of the replication cycle. The genetic material contains basic instructions for the cell to reproduce, hijacking the body's normal production machinery to serve the needs of the virus. Thus, additional copies of the virus are produced leading to more cells becoming infected. Then why use viruses for gene therapy? - because viruses could be good vehicles to transport good genes into the human cell. The scientists remove the genes in the virus that cause disease and replace them with genes encoding the desired effect.

Many gene therapy clinical trials rely on retroviruses or adenoviruses to deliver the desired gene. Other viruses used as vectors include adeno-associated viruses, lentiviruses, pox viruses, alphaviruses, and herpes viruses. These viruses differ in how well they transfer genes to the cells they recognize and are able to infect, and whether they alter the cell's DNA permanently or temporarily.

Viral vectors are defined by three components:

  • the protein capsid and/or envelope
  • the transgene of interest to produce the desired effect
  • the regulatory cassette - which is combined elements that control stable or transient somatic expression of the transgene

Scope and Methodology

The analysis in this Kalorama Information report, “Viral Vectors Market Analysis and Opportunities ”, is based on the author's industry knowledge combined with literature searches and discussions with industry professionals and experts in the areas of viral vector manufacturing companies, pharmaceutical and biotechnology companies, cell and gene therapy companies and research institutes. A combination of company, government, industry, institutional and private sources generate the primary sources of information. It includes information from extensive literature reviews and discussions with experts in the field, including microbiologists, pathologists, hospital authorities, reimbursement specialists, research scientists, business development managers and marketing managers.

All market data are based on manufacturer sales to the end user and not retail pricing or reimbursement payments. Market data pertains to the world market at the manufacturers' level. The base year for data was 2021 with forecast data provided for 2026. Compound annual growth rates (CAGRs) are provided for the 2021-2026 periods for each segment covered. The forecasted market analysis for 2021-2026 is largely based on demographic trends, new developments, cell and gene therapy advancements, company performance trends, merger and acquisitions, and global expansion.

Table of Contents
Product Code: 21-032

TABLE OF CONTENTS

CHAPTER 1: EXECUTIVE SUMMARY

  • OVERVIEW
  • SCOPE AND METHODOLOGY
  • MARKET TRENDS
  • MARKET DRIVERS AND LIMITERS
    • Table 1-1: Viral Vector Market Drivers and Limiters
  • MARKET SUMMARY
    • Table 1-2: Total Viral Vector Market Revenues 2021-2026 (in millions$)
    • Figure 1-1: Viral Vector Market Revenues, 2021-2026 ($ millions)
  • COMPETITIVE LANDSCAPE

CHAPTER 2: INTRODUCTION TO VIRAL VECTORS

  • OVERVIEW
    • Table 2-1: Selected Examples of Viruses in Gene Therapy
  • TYPES OF VIRAL VECTORS
    • Retrovirus
    • Adenovirus
    • HSV Virus
    • Chimeric Virus
    • Other
  • DISEASE PROFILES IN VIRAL VECTOR MARKETS
    • Cancer
    • Figure 2-1: Incidence of Cancer by Type, 2020
    • Figure 2-2: Distribution of Cancer Incidence by Type, 2020
    • Cardiovascular Disease
    • Selected Blood and Genetic Disorders
    • Infectious Diseases

CHAPTER 3: MARKET TRENDS

  • POPULATION AND AGING
    • Table 3-1: Elderly Support Ratio in Various Countries (Australia; Brazil; Canada; China; China, Hong Kong SAR; France; Germany; India; Italy; Japan; Mexico; Saudi Arabia; Singapore; South Africa; Spain; Turkey; United Kingdom; United States; World)
  • ELDERLY POPULATION
    • Figure 3-1: Global Population Trends, Total Population vs. Age 65+ Population, 2000-2050
  • GENE THERAPY AND VIRAL VECTOR USE
  • CANCER AND VIRAL VECTOR USE
  • INFECTIOUS DISEASE AND VIRAL VECTOR USE
  • TRANSDUCTION AND TRANSFECTION
    • Transfection
    • Transduction
  • COMPETING METHODS
    • Electroporation
    • Non-Viral
    • Transposons
  • VIRAL VECTOR SHORTAGES
  • COVID-19 PLATFORMS AND VACCINES
    • Table 3-2: Selected Viral Vector-based COVID-19 Vaccines
  • PRODUCTS IN DEVELOPMENT UTILIZING VIRAL VECTORS
    • Table 3-3: Selected Products in Development Utilizing Viral Vectors

CHAPTER 4: MARKET ANALYSIS

  • Table 4-1: Total Viral Vector Market Revenues 2021-2026 (in millions$)
  • Figure 4-1: Viral Vector Market Revenues, 2021-2026 ($ millions)
  • VIRAL VECTOR MARKET BY VECTOR TYPE
    • Table 4-2: Viral Vector Market by Vector Type 2021-2026 (in millions)
    • Figure 4-2: Viral Vector Market Percentage by Type 2021
    • Figure 4-3: Viral Vector Market Percentage by Type 2026
  • VIRAL VECTOR MARKET SHARE BY DISEASE
    • Figure 4-4: Viral Vector Market Percentage by Disease, 2021
  • VIRAL VECTOR USE BY APPLICATION
    • Figure 4-5: Viral Vector Market Use Percentage by Application 2021
  • VIRAL VECTOR WORKFLOW PROCESSING
    • Figure 4-6: Viral Vector Upstream/Downstream Workflow Percentage, 2021
    • Figure 4-7: Viral Vector Upstream/Downstream Workflow Percentage, 2026
  • VIRAL VECTOR MARKET BY REGION
    • Table 4-3: Global Viral Vector Market Revenues by Geographic Region, 2021-2026 (in millions$)
    • Figure 4-8: Global Viral Vector Market Percent by Geographic Region, 2021
    • Figure 4-9: Global Viral Vector Market Percent by Geographic Region, 2026

CHAPTER 5: COMPETITORS

  • COMPETITIVE LANDSCAPE
    • Figure 5-1: Viral Vector Manufacturing - Pharmaceutical/Biotech companies vs CDMOs - 2021
  • ALLIANCES, ACQUISITIONS AND COLLABORATIONS
    • Table 5-1: Selected Mergers and Acquisitions of Viral Vector Companies
  • EXPANSION OF MANUFACTURING
    • Table 5-2: Selected Recent Viral Vector Company Expansion
  • COMPETITOR ANALYSIS

CHAPTER 6: MARKET PARTICIPANT PROFILES

  • 4D MOLECULAR THERAPEUTICS, INC. (4DMT)
    • Table 6-1: 4DMT Corporate Summary
    • Company Overview
    • Products
    • Performance Review
    • Table 6-2: 4DMT (2019-2020) ($ thousands)
  • ABL INC
    • Table 6-3: ABL Corporate Summary
    • Company Overview
    • Products
  • AGC BIOLOGICS
    • Table 6-4: AGC Biologics Technologies Corporate Summary
    • Company Overview
    • Products
  • AGILENT TECHNOLOGIES
    • Table 6-5: Agilent Technologies Corporate Summary
    • Company Overview
    • Products
    • Performance Review
    • Table 6-6: Agilent (2017-2020) ($ millions)
  • ALDEVRON
    • Table 6-7: Aldevron Corporate Summary
    • Company Overview
    • Products
  • BATAVIA BIOSCIENCES B.V.
    • Table 6-8: Batavia Biosciences Corporate Summary
    • Company Overview
    • Products
  • BIOVIAN OY
    • Table 6-9: Biovian Corporate Summary
    • Company Overview
    • Products
  • CATAPULT CELL AND GENE THERAPY
    • Table 6-10: Catapult Cell and Gene Therapy Corporate Summary
    • Company Overview
    • Products
  • CEVEC PHARMACEUTICALS GMBH
    • Table 6-11: Cevec Pharmaceuticals Corporate Summary
    • Company Overview
    • Products
  • COBRA BIOLOGICS
    • Table 6-12: Cobra Biologics Corporate Summary
    • Company Overview
    • Products
  • CYTIVA LIFE SCIENCES
    • Table 6-13: Cytiva Corporate Summary
    • Company Overview
    • Products
  • GENEZEN
    • Table 6-14: Genezen Corporate Summary
    • Company Overview
    • Products
  • HORIZON DISCOVERY LTD.
    • Table 6-15: Horizon Discovery Corporate Summary
    • Company Overview
    • Products
  • FINVECTOR OY
    • Table 6-16: FinVector Corporate Summary
    • Company Overview
    • Products
  • FUJIFILM DIOSYNTH BIOTECHNOLOGIES
    • Table 6-17: FUJIFILM Diosynth Corporate Summary
    • Company Overview
    • Products
  • LONZA
    • Table 6-18: Lonza Corporate Summary
    • Company Overview
    • Products
    • Performance Review
    • Table 6-19: Lonza (2019-2020) ($ millions)
  • MERCK KGAA/ MILLIPORE SIGMA
    • Table 6-20: Millipore Sigma Corporate Summary
    • Company Overview
    • Products
    • Performance Review
    • Table 6-21: Merck/MilliporeSigma (2019-2020) ($ millions)
  • MIRUS BIO
    • Table 6-22: Mirus Bio Corporate Summary
    • Company Overview
    • Products
  • OXFORD BIOMEDICA PLC.
    • Table 6-23: Agilent Corporate Summary
    • Company Overview
    • Products
    • Performance Review
    • Table 6-24: Oxford Biomedica (2019-2020) ($ millions)
  • REGENXBIO, INC
    • Table 6-25: REGENXBIO Corporate Summary
    • Company Overview
    • Products
    • Performance Review
    • Table 6-26: REGENXBIO (2019-2020) ($ thousands)
  • SANOFI S.A.
    • Table 6-27: Sanofi S.A. Corporate Summary
    • Company Overview
    • Products
  • SIRION BIOTECH
    • Table 6-28: SIRION Biotech Corporate Summary
    • Company Overview
    • Products
  • SPARK THERAPEUTICS, INC
    • Table 6-29: Spark Therapeutics Corporate Summary
    • Company Overview
    • Products
  • TAKARA BIO
    • Table 6-30: Takara Bio Corporate Summary
    • Company Overview
    • Products
  • THERMO FISHER SCIENTIFIC
    • Table 6-31: Thermo Fisher Corporate Summary
    • Company Overview
    • Products
    • Performance Review
    • Table 6-32: Thermo Fisher Scientific (2019-2020) ($ millions)
  • UNIQURE N.V.
    • Table 6-33: uniQure Corporate Summary
    • Company Overview
    • Products
    • Performance Review
    • Table 6-34: uniQure (2019-2020) ($ thousands)
  • VECTOR BIOLABS
    • Table 6-35: Vector Biolabs Corporate Summary
    • Company Overview
    • Products
  • VIGENE BIOSCIENCES
    • Table 6-36: Vigene Biosciences Corporate Summary
    • Company Overview
    • Products
  • VIROCELL BIOLOGICS
    • Table 6-37: ViroCell Biologics Corporate Summary
    • Company Overview
    • Products
  • VIROVEK
    • Table 6-38: Virovek Corporate Summary
    • Company Overview
    • Products
  • VOYAGER THERAPEUTICS
    • Table 6-39: Voyager Therapeutics Corporate Summary
    • Company Overview
    • Products
  • WAISMAN BIOMANUFACTURING
    • Table 6-40: Waisman Biomanufacturing Corporate Summary
    • Company Overview
    • Products
  • YPOSKESI
    • Table 6-41: Yposkesi Corporate Summary
    • Company Overview
    • Products